- Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms
- Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available
- Early access to treatment for managing COVID-19 symptoms is critical to preventing healthcare system overload
Author Archive: AZBio
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
Interim analysis of original cohorts of Phase 1 study evaluated two-dose vaccination schedule of mRNA-1273 across three dose levels (25, 100, 250 µg) in 45 healthy adults ages 18-55 years; results reaffirm and expand upon positive interim data announced on May 18thContinue reading
Beacon Biomedical Launches COVID-19 Antibody Testing
Quantitative IgM and IgG Antibody Test Results Within 48 HoursContinue reading
Pfizer and BioNTech granted FDA Fast Track Designation for Two Investigation mRNA based Vaccine Candidates Against SARS-COV-2
Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020
NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and BNT162b2 are the two most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.Continue reading
TGen Identifies Immune Effects of a Drug in Aggressive Ovarian Cancer that Strikes Young Women
SP-2577 could enable the immune system to attack ovarian cancer; clinical trials for patients expected soonContinue reading
Life Science Industry Launches $1B AMR Action Fund with a Goal of Developing New Antibiotics
The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.Continue reading
TGen-led study identifies unique cells that may drive lung fibrosis
Study with Vanderbilt University shows how the body’s attempts to repair damage may instead contribute to severe lung diseaseContinue reading
NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools
Network website features secure method for volunteering for studies.Continue reading
Aesthetics Biomedical® Names World Renowned Experts to Prestigious Clinical Advisory Board
These physicians are experts in the field representing aesthetics, plastic surgery, and dermatology. Continue reading
BD Launches Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes, Dramatically Expanding Access to COVID-19 Testing
- Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settings
- BD will begin shipping the new test this week and expects to ramp-up manufacturing capacity to 2 million tests per week by the end of September
- This is the company’s third diagnostic test to receive Emergency Use Authorization by U.S. FDA for detecting COVID-19